MYB and adrenal cortex carcinoma: Notably, the high cost and complexity are some of the barriers that make it difficult to include more comprehensive and specific methods in the clinical routine, such as Next Generation Sequencing (NGS) and RNA in situ hybridization (ISH), evaluating the MYB-NFIB fusion routine a standard in the ACC cases a challenge (39, 40).